More specifically in the context of CIN, drugs or genetic drivers that decrease mitotic fidelity have been found to lead to activation of STAT1 signaling, indicated by increased levels of phosphorylated STAT1 in various cancer types, including breast cancer (Bakhoum et al. 2018; Hong et al. 2022) and acute myeloid leukemia (Jin et al. 2020). The gene discussed is STAT1; the disease is acute myeloid leukemia.